Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin + DPd in RRMM
NCT05581875Phase 2Not yet recruiting
- Sponsor
- Hellenic Society of Hematology
- Start
- Oct 2022
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of belantamab mafodotin in multiple myeloma (MM), sponsored by Hellenic Society of Hematology. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05581875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05581875.